
VeonGen aligns with FDA on phase 3 design for VG801, a dual-AAV Stargardt gene therapy, after uncontrolled phase 1/2 BCVA gains.
Benjamin Bakall, MD, PhD, weighs the RESTORE efficacy and safety data, the practical realities of in-office delivery, and how genotype-independent treatment reshapes candidacy and patient counseling.
The US Food and Drug Administration (FDA) recently accepted Nanoscope Therapeutics’ biologics license application (BLA) for sonpiretigene isteparvovec (MOGENRY, formerly MCO-010), an investigational gene-agnostic optogenetic therapy for retinitis pigmentosa (RP) with severe vision loss.





